Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...
Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s the second time the firm ...
Zacks Investment Research on MSN
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
Novavax (NVAX) stock in focus as the company boosts 2025 revenue outlook after better than expected Q3 revenue driven by ...
Asianet Newsable on MSN
Novavax Stock Faces Retail Backlash As Shah Capital Warns Of Proxy Fight And Presses For A Sale
Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...
Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership with ...
Shares of Novavax Inc. NVAX shed 3.48% to $8.59 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.08% to 23,024.63 ...
The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback